Testování použití vyšetřovaných léků Atezolizumab a/nebo Bevacizumab se standardní chemoterapií nebo bez ní ve druhé linii léčby pokročilého stadia rakoviny hlavy a krku
Studie fáze II/III chemoterapie + cetuximab vs chemoterapie + bevacizumab vs atezolizumab + bevacizumab po progresi inhibice kontrolního bodu imunitního systému u recidivujících/metastatických karcinomů hlavy a krku
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
- Recidivující spinocelulární karcinom hlavy a krku
- Recidivující hypofaryngeální spinocelulární karcinom
- Recidivující spinocelulární karcinom hrtanu
- Metastatický spinocelulární karcinom hlavy a krku
- Klinické stadium IV HPV-zprostředkovaný (p16-pozitivní) orofaryngeální karcinom AJCC v8
- Stádium IV hypofaryngeálního karcinomu AJCC v8
- Rakovina hrtanu stadia IV AJCC v8
- Rakovina rtů a dutiny ústní fáze IV AJCC v8
- Fáze IV orofaryngeálního (p16-negativního) karcinomu AJCC v8
- Metastatický hypofaryngeální spinocelulární karcinom
- Metastatický spinocelulární karcinom hrtanu
- Metastatický karcinom rtů a dutiny ústní
- Metastatický spinocelulární karcinom nosní dutiny
- Metastatický spinocelulární karcinom nosohltanu
- Metastatický spinocelulární karcinom hltanu
- Metastatický sinonazální spinocelulární karcinom
- Recidivující spinocelulární karcinom rtů a ústní dutiny
- Recidivující spinocelulární karcinom nosohltanu
- Recidivující spinocelulární karcinom hltanu
- Recidivující sinonazální spinocelulární karcinom
- Stádium IV nasofaryngeálního karcinomu AJCC v8
- Sinonazální rakovina stadia IV AJCC v8
- Stage IV hlava a krk kožní spinocelulární karcinom AJCC V8
Intervence / Léčba
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.
PHASE II: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening.
ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
PHASE III: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Dublin, California, Spojené státy, 94568
- Epic Care-Dublin
-
Emeryville, California, Spojené státy, 94608
- Epic Care Partners in Cancer Care
-
Irvine, California, Spojené státy, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Martinez, California, Spojené státy, 94553-3156
- Contra Costa Regional Medical Center
-
Orange, California, Spojené státy, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Spojené státy, 94304
- VA Palo Alto Health Care System
-
Palo Alto, California, Spojené státy, 94304
- Stanford Cancer Institute Palo Alto
-
-
Connecticut
-
Derby, Connecticut, Spojené státy, 06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield, Connecticut, Spojené státy, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury, Connecticut, Spojené státy, 06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Spojené státy, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Spojené státy, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Spojené státy, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Spojené státy, 06520
- Yale University
-
North Haven, Connecticut, Spojené státy, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Orange, Connecticut, Spojené státy, 06477
- Smilow Cancer Hospital-Orange Care Center
-
Stamford, Connecticut, Spojené státy, 06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington, Connecticut, Spojené státy, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Spojené státy, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Spojené státy, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Spojené státy, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Spojené státy, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Spojené státy, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Coral Gables, Florida, Spojené státy, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Spojené státy, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale, Florida, Spojené státy, 33316
- Broward Health Medical Center
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Spojené státy, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Spojené státy, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Spojené státy, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Spojené státy, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Spojené státy, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Spojené státy, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Spojené státy, 96701
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Spojené státy, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Spojené státy, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Spojené státy, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Spojené státy, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Spojené státy, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Spojené státy, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Spojené státy, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Spojené státy, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Spojené státy, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Spojené státy, 60612
- University of Illinois
-
Chicago, Illinois, Spojené státy, 60612
- John H Stroger Jr Hospital of Cook County
-
Danville, Illinois, Spojené státy, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Spojené státy, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Spojené státy, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Spojené státy, 62401
- Carle Physician Group-Effingham
-
Harvey, Illinois, Spojené státy, 60426
- Ingalls Memorial Hospital
-
Mattoon, Illinois, Spojené státy, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Spojené státy, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Spojené státy, 62269
- Cancer Care Center of O'Fallon
-
O'Fallon, Illinois, Spojené státy, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Spojené státy, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Spojené státy, 62702
- Springfield Clinic
-
Springfield, Illinois, Spojené státy, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
Yorkville, Illinois, Spojené státy, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Spojené státy, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Spojené státy, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Spojené státy, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Spojené státy, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Spojené státy, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Spojené státy, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Spojené státy, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Spojené státy, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Spojené státy, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Spojené státy, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Spojené státy, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Spojené státy, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Spojené státy, 50266
- Mercy Medical Center-West Lakes
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70112
- University Medical Center New Orleans
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Spojené státy, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland/Greenebaum Cancer Center
-
Cumberland, Maryland, Spojené státy, 21502
- UPMC Western Maryland
-
-
Massachusetts
-
Worcester, Massachusetts, Spojené státy, 01655
- UMass Memorial Medical Center - University Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, Spojené státy, 55433
- Mercy Hospital
-
Minneapolis, Minnesota, Spojené státy, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Spojené státy, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Spojené státy, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Spojené státy, 63703
- Saint Francis Medical Center
-
St Louis, Missouri, Spojené státy, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Spojené státy, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Spojené státy, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Spojené státy, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Spojené státy, 59405
- Benefis Sletten Cancer Institute
-
Missoula, Montana, Spojené státy, 59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Spojené státy, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Spojené státy, 88011
- Memorial Medical Center-Las Cruces
-
-
North Carolina
-
Clinton, North Carolina, Spojené státy, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Spojené státy, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Spojené státy, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Centerville, Ohio, Spojené státy, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Spojené státy, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Spojené státy, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Spojené státy, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Spojené státy, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Spojené státy, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Spojené státy, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Spojené státy, 45429
- Kettering Medical Center
-
Steubenville, Ohio, Spojené státy, 43952
- Trinity's Tony Teramana Cancer Center
-
Toledo, Ohio, Spojené státy, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Spojené státy, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Spojené státy, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Spojené státy, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Spojené státy, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Spojené státy, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, Spojené státy, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Spojené státy, 15009
- UPMC-Heritage Valley Health System Beaver
-
Butler, Pennsylvania, Spojené státy, 16001
- UPMC Hillman Cancer Center at Butler Health System
-
Camp Hill, Pennsylvania, Spojené státy, 17011
- UPMC Camp Hill
-
Carlisle, Pennsylvania, Spojené státy, 17015
- Carlisle Regional Cancer Center
-
Cranberry Township, Pennsylvania, Spojené státy, 16066
- UPMC Hillman Cancer Center - Passavant - Cranberry
-
Erie, Pennsylvania, Spojené státy, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Spojené státy, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Spojené státy, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville, Pennsylvania, Spojené státy, 16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Harrisburg, Pennsylvania, Spojené státy, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Indiana, Pennsylvania, Spojené státy, 15701
- IRMC Cancer Center
-
Johnstown, Pennsylvania, Spojené státy, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, Spojené státy, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Spojené státy, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Spojené státy, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Spojené státy, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Spojené státy, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Mount Pleasant, Pennsylvania, Spojené státy, 15666
- UPMC Hillman Cancer Center - Part of Frick Hospital
-
N. Huntingdon, Pennsylvania, Spojené státy, 15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
Natrona Heights, Pennsylvania, Spojené státy, 15065
- UPMC Cancer Center-Natrona Heights
-
New Castle, Pennsylvania, Spojené státy, 16105
- UPMC Hillman Cancer Center - New Castle
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Spojené státy, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Spojené státy, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Spojené státy, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15219
- UPMC-Mercy Hospital
-
Seneca, Pennsylvania, Spojené státy, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Spojené státy, 15401
- UPMC Cancer Center-Uniontown
-
Washington, Pennsylvania, Spojené státy, 15301
- UPMC Cancer Center-Washington
-
West Mifflin, Pennsylvania, Spojené státy, 15122
- UPMC West Mifflin-Cancer Center Jefferson
-
Williamsport, Pennsylvania, Spojené státy, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Spojené státy, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Spojené státy, 17408
- UPMC Memorial
-
-
Rhode Island
-
Westerly, Rhode Island, Spojené státy, 02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Spojené státy, 37932
- Covenant Health Cancer Centers - West
-
Lenoir City, Tennessee, Spojené státy, 37772
- Covenant Health Oncology Group - Lenoir City
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University/Ingram Cancer Center
-
Oak Ridge, Tennessee, Spojené státy, 37830
- Covenant Health Oncology Group - Oak Ridge
-
-
Vermont
-
Saint Johnsbury, Vermont, Spojené státy, 05819
- Dartmouth Cancer Center - North
-
-
West Virginia
-
Charleston, West Virginia, Spojené státy, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Mukwonago, Wisconsin, Spojené státy, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Spojené státy, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Waukesha, Wisconsin, Spojené státy, 53188
- UW Cancer Center at ProHealth Care
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma [SCC] of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin)
-
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible
-
Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization.
- NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study
-
Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial
-
Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration
-
Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy:
- Prior carotid bleeding,
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies,
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies,
- Any prior history of bleeding related to the current head and neck cancer,
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization
-
Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism
-
Patient must not have a history of coagulopathy or hemorrhagic disorders
-
Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed)
-
Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents [e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function
-
Patient must have PD-L1 expression >= 1% by CPS in the tumor and/or immune cells
- NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility
-
Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis
-
Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy
-
Patient must not have a history of solid organ transplantation or stem-cell transplant
-
Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions
-
Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded
-
Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
- NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria)
-
Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization)
-
Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX [registered trademark])
-
Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization
-
Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period
-
Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment
-
Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
-
Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Aktivní komparátor: Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo PET scan
Ostatní jména:
Given IV
Ostatní jména:
|
|
Experimentální: Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo PET scan
Ostatní jména:
|
|
Experimentální: Phase II, Arm C (Bevacizumab, Atezolizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo PET scan
Ostatní jména:
Given IV
Ostatní jména:
|
|
Experimentální: Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo PET scan
Ostatní jména:
Given IV
Ostatní jména:
|
|
Experimentální: Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)
Patients receive treatment as in Arm B or C above based on results of the Phase II trial. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo ECHO
Ostatní jména:
Undergo CT scan
Ostatní jména:
Undergo PET scan
Ostatní jména:
Given IV
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Přežití bez progrese (PFS) (fáze II)
Časové okno: Doba od zahájení léčby do progrese onemocnění nebo smrti, hodnocená do 5 let od randomizace
|
Doba od zahájení léčby do progrese onemocnění nebo smrti, hodnocená do 5 let od randomizace
|
|
|
Overall survival (OS) (Phase III)
Časové okno: Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Will be compared using a stratified log rank test. |
Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Výskyt nežádoucích účinků (fáze III)
Časové okno: Až 30 dní po ukončení léčby
|
Až 30 dní po ukončení léčby
|
|
|
OS in the subset of patients with high PD-L1 expression (Phase III)
Časové okno: Up to 5 years from randomization
|
The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model. |
Up to 5 years from randomization
|
|
Correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers
Časové okno: Up to 5 years from randomization
|
The two-sample t-test will be used to compare the difference of baseline 18F -FDG PET /CT imaging biomarkers (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) between low and high expression of PD-L1. |
Up to 5 years from randomization
|
|
Prediction of treatment response
Časové okno: Baseline up to 12 weeks
|
Determined by 18FDG-PET/CT and CT neck imaging biomarkers. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post-treatment, PFS, and OS Logistic regression model will be fit to assess the association of the 18F -FDG PET /CT imaging biomarkers (e.g., SUVmax, MTV, TLG, tumor heterogeneity, tumor volume) with binary treatment response at 9-12 weeks post treatment. Cox proportional hazards models will be fit to assess the association of 18F -FDG PET /CT imaging biomarkers with time-to-event outcomes (PFS or OS). |
Baseline up to 12 weeks
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression
Časové okno: Up to 5 years from randomization
|
The imaging textural features from radiomics analysis will be associated with the dichotomized PD-L1 expressions. First, proper transformation will be applied to the textural features as needed to address the distribution skewness. Second, Pearson or Spearman rank correlations will be calculated between all pairs of textural features to identify highly correlated features. Third, to address overfitting and high collinearity, machine learning techniques (e.g., LASSO or XGBoost) will be employed for feature selection during the association analysis with PD-L1 expressions. |
Up to 5 years from randomization
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Aarti Bhatia, ECOG-ACRIN Cancer Research Group
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci úst
- Stomatognátní onemocnění
- Novotvary podle místa
- Novotvary
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Novotvary hlavy a krku
- Novotvary, žlázové a epiteliální
- Novotvary dýchacího traktu
- Otorinolaryngologická onemocnění
- Novotvary hltanu
- Otorinolaryngologické novotvary
- Nemoci nosohltanu
- Faryngeální onemocnění
- Karcinom, skvamózní buňky
- Nemoci hrtanu
- Novotvary nosohltanu
- Karcinom nosohltanu
- Spinocelulární karcinom hlavy a krku
- Karcinom
- Novotvary hrtanu
- Novotvary v ústech
- Orofaryngeální novotvary
- Novotvary hypofaryngu
- Lymfoidní intersticiální pneumonie
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Sloučeniny síry
- Organické chemikálie
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Uhlovodíky
- Cykloparafiny
- Uhlovodíky, alicyklické
- Uhlovodíky, cyklické
- Terpeny
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Anorganické chemikálie
- Sloučeniny chloru
- Sloučeniny dusíku
- Koordinační komplexy
- Taxoidy
- Cyclodecanes
- Diterpeny
- Prvky
- Kovy
- Techniky chemie, analytické
- Analýza spektra
- Kovy, těžké
- Izotypy imunoglobulinu
- Sulfidy
- Anionty
- Ionty
- Elektrolyty
- Sirovodík
- Platinové sloučeniny
- Přechodové prvky
- Docetaxel
- Bevacizumab
- Cetuximab
- Karboplatina
- Imunoglobulin G
- Cisplatina
- 1,2-diaminocyklohexanplatina II citrát
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Disulfidy
- Platina
- Atezolizumab
- (225) AC-DOTA-C (RGDYK)
Další identifikační čísla studie
Další identifikační čísla studie
- NCI-2021-10021
- U10CA180820 (Grant/smlouva NIH USA)
- NCI-2021-10021 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- EA3202 (Jiný identifikátor: CTEP)
- EA3202 (Jiný identifikátor: ECOG-ACRIN Cancer Research Group)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .